Vitanova Life Sciences Corp (VNOV) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Vitanova Life Sciences Corp (VNOV) stock forecast summary
Our AI ranks Vitanova Life Sciences Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Vitanova Life Sciences Corp is a small-cap company with a market capitalization of $33M.
For VNOV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 22.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VNOV included.
Follow VNOV freeVNOV price chart and AI forecast
How VNOV ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Vitanova Life Sciences Corp (VNOV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Apparel, Piece Goods & Notions peers listed below that report each metric.
Valuation & Market
| Metric | VNOV | Rank |
|---|---|---|
| Market Cap | $33M | – |
| P/E Ratio | 49.99x | – |
| P/B Ratio | 17.30x | – |
| EPS | $0.08 | – |
| Book Value/Share | $0.23 | – |
| Revenue/Share | $0.39 | – |
Profitability & Margins
| Metric | VNOV | Rank |
|---|---|---|
| ROE | -1.8% | – |
| ROA | -1.5% | – |
| ROIC | -4.5% | – |
| Gross Margin | 25.0% | – |
| Operating Margin | -2.5% | – |
| Net Margin | -1.0% | – |
| EBT Margin | -2.4% | – |
| Tax Rate | -37.2% | – |
Financial Health
| Metric | VNOV | Rank |
|---|---|---|
| Current Ratio | 7.13x | – |
| Quick Ratio | 6.17x | – |
| D/E Ratio | 0.16x | – |
| Financial Leverage | 1.16x | – |
| Interest Coverage | 690.2x | – |
| Working Capital | $2M | – |
Cash Flow
| Metric | VNOV | Rank |
|---|---|---|
| Operating Cash Flow | $560K | 2/5 |
| OCF Growth YoY | -42.0% | – |
Operational Efficiency
| Metric | VNOV | Rank |
|---|---|---|
| Asset Turnover | 1.45x | – |
| Receivables Turnover | 10.2x | – |
| Inventory Turnover | 7.9x | – |
| Days Sales Outstanding | 36 days | – |
| Days Inventory | 46 days | – |
| Payables Period | 19 days | – |
| Cash Conversion Cycle | 63 days | – |
Income Statement
| Metric | VNOV | Rank |
|---|---|---|
| Total Revenue | $3M | – |
| Operating Income | -$90K | 4/5 |
| Net Income | -$30K | 4/5 |
| SG&A Expense | $740K | – |
| Cost of Goods Sold | $2M | – |
Dividend & Shareholder Information
| Metric | VNOV | Rank |
|---|---|---|
| Shares Outstanding | 8M | – |
| Net Income Growth | -104.0% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2M | 99.2% of assets |
| Cash & Short-term Investments | $2M | 71.5% of assets |
| Accounts Receivable | $320K | 14.3% of assets |
| Inventory | $300K | 13.4% of assets |
| Total Liabilities | $310K | 13.9% of assets |
| Short-term Debt | $190K | 8.5% of assets |
VNOV quarterly financials and insider trading
Vitanova Life Sciences Corp (VNOV) industry peers
Companies classified under the same SEC industry code as Vitanova Life Sciences Corp (Wholesale-Apparel, Piece Goods & Notions): 5 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere VNOV sits on the market map
Vitanova Life Sciences Corp (VNOV) stock news
Loading...
Vitanova Life Sciences Corp (VNOV) stock forecast FAQ
What is the Vitanova Life Sciences Corp (VNOV) stock forecast?
Our AI ranks Vitanova Life Sciences Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Vitanova Life Sciences Corp stock predictions?
For VNOV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 22.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Vitanova Life Sciences Corp forecasts updated?
Vitanova Life Sciences Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Vitanova Life Sciences Corp's industry peers?
5 issuers in our coverage, VNOV included, share the SEC industry code Wholesale-Apparel, Piece Goods & Notions. The largest are: Weyco Group Inc (WEYS), Stark Focus Group, Inc. (SKFG), Authentic Holdings, Inc. (AHRO), Keemo Fashion Group Ltd (KMFG).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.